



Average FY Product Sales Consensus

€m	2021a	2022e	2023e	2024e	2025e	2026e	2027e	Peak Sales	NPV*
Product Portfolio									
Cimzia	1,841	2,015	2,073	1,990	1,760	1,450	1,178		4,954
Vimpat	1,549	977	610	501	435	386	351		2,151
Keppra	970	756	666	606	561	519	486		2,260
Briviact	355	449	524	589	642	581	351	656	1,585
Neupro	307	285	256	227	208	194	171		703
Evenity**		694	838	968	1,082	1,123	1,118		
Nayzilam	57	87	114	140	158	167	162	202	455
Bimzelx	4	57	236	616	1,034	1,450	1,887	3,140	7,124
Fintepla		111	251	377	497	593	649	853	1,845
Potential new products**									
Zilucoplan		0	39	161	296	456	637	1,034	2,709
Rozanolixizumab (Rozimab)		0	30	124	251	416	591	1,017	1,710
Dapimab		0	0	5	42	171	223		
Staccato alprazolam		0	1	17	53	96	145	294	459
Bepranemab		0	0	9	37	55	49		

* If NPV cell blank: not sufficient data available

**global sales, non-risk adj.

Median FY Product Sales Consensus

€m	2021a	2022e	2023e	2024e	2025e	2026e	2027e	Peak Sales	NPV*
Product Portfolio									
Cimzia	1,841	2,040	2,076	1,961	1,714	1,385	1,173		4,966
Vimpat	1,549	995	606	518	462	407	380		1,635
Keppra	970	756	657	590	538	490	454		2,024
Briviact	355	450	528	584	646	585	342	654	1,684
Neupro	307	290	265	211	200	190	173		600
Evenity**		678	836	946	1,069	1,049	1,030		
Nayzilam	57	86	116	139	156	161	167	200	402
Bimzelx	4	50	237	610	988	1,445	1,884	2,995	6,776
Fintepla		111	233	363	495	600	652	800	1,300
Potential new products**									
Zilucoplan		0	45	167	304	432	675	1,105	2,467
Rozanolixizumab (Rozimab)		0	26	125	251	385	540	932	1,768
Dapimab		0	0	0	50	180	225		
Staccato alprazolam		0	0	18	42	72	119	255	500
Bepranemab		0	0	0	0	5	40		

* If NPV cell blank: not sufficient data available

**global sales, non-risk adj.

Based on the estimates of 17 brokers

Last updated: 15/07/22